AbstractBackgroundThe aim of this study is to investigate the profiles of gut microbiota and metabolites in acute myelocytic leukemia (AML) patients treated with/without chemotherapy.MethodsHerein, high‐throughput 16S rRNA gene sequencing was performed to analysis gut microbiota profiles, and liquid chromatography and mass spectrometry were performed to analysis metabolites profiles. The correlation between gut microbiota biomarkers identified by LEfSe and differentially expressed metabolites were determined by spearman association analysis.ResultsThe results showed the distinguished gut microbiota and metabolites profiles between AML patients and control individuals or AML patients treated with chemotherapy. Compared to normal populations, the ratio of Firmicutes to Bacteroidetes was increased at the phylum level than that in AML patients, and LEfSe analysis identified Collinsella and Coriobacteriaceae as biomarkers of AML patients. Differential metabolite analysis indicated that, compared to AML patients, numerous differential amino acids and analogs could be observed in control individuals and AML patients treated with chemotherapy. Interestingly, spearman association analysis demonstrated that plenty of bacteria biomarkers shows statistical correlations with differentially expressed amino acid metabolites. In addition, we found that both Collinsella and Coriobacteriaceae demonstrate remarkable positive correlation with hydroxyprolyl‐hydroxyproline, prolyl‐tyrosine, and tyrosyl‐proline.ConclusionIn conclusion, our present study investigated the role of the gut‐microbiome–metabolome axis in AML and revealed the possibility of AML treatment by gut‐microbiome–metabolome axis in the further.

More from our Archive

• DOI: 10.1200/jco.23.00933 2023

  Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update

  William Dale, Heidi D. Klepin, Grant R. Williams, Shabbir M.H. Alibhai, Cristiane Bergerot, Karlynn Brintzenhofeszoc, Judith O. Hopkins, Minaxi P. Jhawer, Vani Katheria, Kah Poh Loh, Lisa M. Lowenstein, June M. McKoy, Vanita Noronha, Tanyanika Phillips, Ashley E. Rosko, Tracy Ruegg, Melody K. Schiaffino, John F. Simmons, Ishwaria Subbiah, William P. Tew, Tracy L. Webb, Mary Whitehead, Mark R. Somerfield, Supriya G. Mohile

• DOI: 10.1097/cej.0000000000000822 2023

  Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia

  Giorgio Bogani, Francesco Sopracordevole, Andrea Ciavattini, Enrico Vizza, Paolo Vercellini, Andrea Giannini, Fabio Ghezzi, Giovanni Scambia, Francesco Raspagliesi, Violante Di Donato,

• DOI: 10.1200/jco.23.00515 2023

  Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

  Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, YuKyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric

• DOI: 10.3390/cancers15143608 2023

  Deep Learning for Medical Image-Based Cancer Diagnosis

  Xiaoyan Jiang, Zuojin Hu, Shuihua Wang, Yudong Zhang

• DOI: 10.1001/jamaoncol.2023.2283 2023

  Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer

  Ning Li, Jianqing Zhu, Rutie Yin, Jing Wang, Lingya Pan, Beihua Kong, Hong Zheng, Jihong Liu, Xiaohua Wu, Li Wang, Yi Huang, Ke Wang, Dongling Zou, Hongqin Zhao, Chunyan Wang, Weiguo Lu, An Lin, Ge Lou, Guiling Li, Pengpeng Qu, Hongying Yang, Yu Zhang, Hongbing Cai, Yueyin Pan, Min Hao, Ziling Liu, Heng Cui, Yingjie Yang, Shuzhong Yao, Xiaoa Zhen, Wenzhao Hang, Jianmei Hou, Juan Wang, Lingying Wu

• DOI: 10.3390/cancers15143565 2023

  Within-Modality Synthesis and Novel Radiomic Evaluation of Brain MRI Scans

  Seyed Masoud Rezaeijo, Nahid Chegeni, Fariborz Baghaei Naeini, Dimitrios Makris, Spyridon Bakas

• DOI: 10.1200/jco.23.00433 2023

  Targeting the Androgen Signaling Axis in Prostate Cancer

  Charles Dai, Scott M. Dehm, Nima Sharifi

• DOI: 10.1001/jamaoncol.2023.2132 2023

  Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

  Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, Willeke Danckaert, Els Goetghebeur, Robbe Van den Begin, Dirk Van Gestel, Vincent Renard, Piet Dirix, Piet Ost

• DOI: 10.1093/jncimonographs/lgad017 2023

  A health equity framework to support the next generation of cancer population simulation models

  Christina Chapman, Jinani Jayasekera, Chiranjeev Dash, Vanessa Sheppard, Jeanne Mandelblatt

• DOI: 10.3390/cancers15143634 2023

  Overview of Pancreatic Cancer Epidemiology in Europe and Recommendations for Screening in High-Risk Populations

  Olga Partyka, Monika Pajewska, Daria Kwaśniewska, Aleksandra Czerw, Andrzej Deptała, Michał Budzik, Elżbieta Cipora, Izabela Gąska, Lucyna Gazdowicz, Aneta Mielnik, Katarzyna Sygit, Marian Sygit, Edyta Krzych-Fałta, Daria Schneider-Matyka, Szymon Grochans, Anna M. Cybulska, Jarosław Drobnik, Ewa Bandurska, Weronika Ciećko, Piotr Ratajczak, Karolina Kamecka, Michał Marczak, Remigiusz Kozłowski